JP2024513492A5 - - Google Patents

Info

Publication number
JP2024513492A5
JP2024513492A5 JP2023561858A JP2023561858A JP2024513492A5 JP 2024513492 A5 JP2024513492 A5 JP 2024513492A5 JP 2023561858 A JP2023561858 A JP 2023561858A JP 2023561858 A JP2023561858 A JP 2023561858A JP 2024513492 A5 JP2024513492 A5 JP 2024513492A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
pharmaceutical composition
inhibitor
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513492A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023394 external-priority patent/WO2022216648A1/en
Publication of JP2024513492A publication Critical patent/JP2024513492A/ja
Publication of JP2024513492A5 publication Critical patent/JP2024513492A5/ja
Pending legal-status Critical Current

Links

JP2023561858A 2021-04-08 2022-04-05 がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 Pending JP2024513492A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172639P 2021-04-08 2021-04-08
US63/172,639 2021-04-08
US202163252998P 2021-10-06 2021-10-06
US63/252,998 2021-10-06
PCT/US2022/023394 WO2022216648A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024513492A JP2024513492A (ja) 2024-03-25
JP2024513492A5 true JP2024513492A5 (enExample) 2025-04-14

Family

ID=81748231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561858A Pending JP2024513492A (ja) 2021-04-08 2022-04-05 がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法

Country Status (9)

Country Link
US (2) US12128048B2 (enExample)
EP (1) EP4319754A1 (enExample)
JP (1) JP2024513492A (enExample)
KR (1) KR20230167053A (enExample)
AU (1) AU2022253455A1 (enExample)
CA (1) CA3214530A1 (enExample)
IL (1) IL307392A (enExample)
MX (1) MX2023011856A (enExample)
WO (1) WO2022216648A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500385A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
KR102871791B1 (ko) * 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
EP4442680A4 (en) * 2021-11-30 2026-05-06 Abbisko Therapeutics Co Ltd Pyrazole derivative, its preparation process and its use in medicine
EP4458812A1 (en) * 2021-12-27 2024-11-06 Medshine Discovery Inc. Pyrazole-1(2h)-phthalazinone compound and application thereof
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
WO2024022186A1 (zh) * 2022-07-29 2024-02-01 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024137778A1 (en) * 2022-12-21 2024-06-27 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2024174980A1 (zh) * 2023-02-21 2024-08-29 正大天晴药业集团股份有限公司 含有二氢酞嗪和烯基的化合物及其用途
WO2025157289A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
US20250312343A1 (en) * 2024-04-08 2025-10-09 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843856B (zh) 2016-05-18 2023-05-02 米拉蒂治疗股份有限公司 Kras g12c抑制剂
KR102861303B1 (ko) 2017-11-15 2025-09-17 미라티 테라퓨틱스, 인크. Ｋｒａｓ ｇ12ｃ 억제제
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021176819A (ja) * 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
US20210230170A1 (en) 2018-08-31 2021-07-29 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
US11492351B2 (en) * 2019-09-12 2022-11-08 Mirati Therapeutics, Inc. MTA-cooperative PRMT5 inhibitors
CR20220175A (es) * 2019-10-22 2022-06-21 Lupin Ltd Combinación farmacéutica de inhibidores de PRMT5

Similar Documents

Publication Publication Date Title
JP2024513494A5 (enExample)
JP6722200B2 (ja) 複素環化合物の合成
KR101993867B1 (ko) 1,2,4-트리아진-4-아민 유도체들
HRP20230472T1 (hr) Novi derivati hidroksikiseline, postupak njihove priprave i farmaceutski sastavi koji ih sadrže
JP2020502049A5 (enExample)
JP2021523159A5 (enExample)
JP2021523112A5 (enExample)
JP2009515988A5 (enExample)
WO2009074575A3 (en) Organic compounds
JP2014520898A5 (enExample)
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
CN110292580A (zh) 用于制备抗癌剂al3818、其结晶形式和其盐的方法
RU2013151803A (ru) Бициклические гетероциклические соединения и их применения в терапии
RU2004117907A (ru) Лиганды каннабиноидных рецепторов
JP2004513882A5 (enExample)
JP2010540602A5 (enExample)
TWI685498B (zh) 新穎之巨環化合物，其製備方法及含彼之藥物組合物
JP2017525757A5 (enExample)
FR3008975A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2014113926A (ru) АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ
JP2009534398A5 (enExample)
JP2006507355A5 (enExample)
JP2011517453A5 (enExample)
JP2013536235A5 (enExample)
WO2022042711A1 (zh) 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体